Background: analogues of prostaglandin are usually the first-line prescribed drops therapy in patients with glaucoma, but the mechanism of their action is not completely understood.
Objectives: Our study aims to compare anterior scleral thickness in glaucoma patients taking prostaglandins vs dorzolamide/timolol combinations
Patients and methods: This was a interventional prospective randomized study that included 60 adults with primary OAG randomized to receive either PG analogues or Dorzolamide/Timolol fixed combination drugs. The AST was evaluated manually by the built-in calibers of a plateform provided in the OCT tools at three locations (scleral spur, 1000 μm, and 2000 μm behind the scleral spur) in the temporal and nasal meridians.
Results: The AST at the nasal area showed a decrease of 15.5 microns (SD = 21.4, p = .000). 1000-micron posterior to it, a decrease of 11.5 microns (SD = 5.5, p = .000), and 2000-micron posterior to it, 9.3 (SD = 6.3, p = .000). The AST at the temporal area demonstrated a decrease of 22.3 microns (SD = 8.6, p = .000). 1000-micron posterior to it, 20.9 microns (SD = 14, p = .000), and 2000-micron posterior to it, 20 microns (SD = 13.2, p = .000)
Conclusion: The use of prostaglandin analogues and dorzolamide/timolol showed a significant decrease in anterior scleral thickness in all measured points; over the nasal and temporal scleral spurs, and 1000 microns posterior to them, and 2000 microns posterior to them with no statistically significant difference between the two drugs.